OMEROS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.36 USD | +1.20% |
|
+0.30% | +2.75% |
| May. 16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| May. 15 | Transcript : Omeros Corporation, Q1 2024 Earnings Call, May 15, 2024 |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.5M | Capitalization | 195M |
|---|---|---|---|---|---|
| Net income 2024 * | -154M | Net income 2025 * | -144M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 30 x |
| P/E ratio 2024 * |
-1.39
x | P/E ratio 2025 * |
-1.69
x | Employees | 198 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Omeros Corporation
More recommendations
More press releases
| 1 day | +1.20% | ||
| 1 week | +0.30% | ||
| 1 month | +6.67% | ||
| 3 months | -25.33% | ||
| 6 months | +53.42% | ||
| Current year | +2.75% |
1 week
3.28
3.44
1 month
3.004.34
Current year
2.615.14
1 year
0.927.80
3 years
0.9216.62
5 years
0.9225.46
10 years
0.9230.23
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 94-06-15 | |
Michael Jacobsen
DFI | Director of Finance/CFO | 65 | 13-07-31 |
Andreas Grauer
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 12-09-26 |
Leroy Hood
BRD | Director/Board Member | 85 | 01-02-28 |
Thomas Cable
BRD | Director/Board Member | 84 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.36 | +1.20% | 207,765 |
| 24-05-30 | 3.32 | +0.61% | 394,157 |
| 24-05-29 | 3.3 | -0.45% | 193,598 |
| 24-05-28 | 3.315 | -1.04% | 210,632 |
| 24-05-24 | 3.35 | +1.82% | 110,574 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Companyâs lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Calendar
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.36
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.75% | 195M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- OMER Stock
